- In March 2021, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, announced that it received approval from the U.S. Food and Drug Administration (FDA) for PONVORY (ponesimod) as a treatment for multiple sclerosis. This approval marks a significant advancement in the available therapies for managing this chronic condition. With PONVORY now authorized for use, patients have access to a new option that may enhance their treatment outcomes and improve their quality of life
- In March 2021, Genentech announced that it received approval from the U.S. Food and Drug Administration (FDA) for the subcutaneous injection of Actemra (tocilizumab) to treat systemic sclerosis-associated interstitial lung disease. This approval represents a significant milestone in expanding treatment options for patients suffering from this challenging condition. With Actemra now available in a subcutaneous form, it offers a more convenient administration route, potentially improving adherence and patient outcomes
